Drugs & Targets FDA accepts for priority review application for anti-BCMA CAR T-cell therapy idecabtagene vicleucel (Ide-cel, bb2121) September 25, 2020Vol.46 No.36
Drugs & Targets Agenus begins rolling BLA submission of balstilimab to FDA for treatment of recurrent/metastatic cervical cancer September 25, 2020Vol.46 No.36
Drugs & Targets FDA accepts sNDA for Xalkori for pediatric ALK-positive anaplastic large cell lymphoma September 25, 2020Vol.46 No.36
Drugs & Targets EMA’s CHMP issues positive opinion for Zejula in ovarian cancer indication September 25, 2020Vol.46 No.36
Drugs & TargetsFree Rhenium NanoLiposomes receives Fast Track Designation from FDA for glioblastoma treatment September 18, 2020Vol.46 No.35
Drugs & TargetsFree Elicio Therapeutics and Moffitt collaborate to study AMP-CD19 + CD19 CAR T cells September 18, 2020Vol.46 No.35
Drugs & TargetsFree UCSD, Cofactor Genomics collaborate to improve patient outcomes in metastatic head and neck cancer September 18, 2020Vol.46 No.35
Drugs & Targets Pralsetinib receives FDA approval for lung cancer with RET gene fusions September 11, 2020Vol.46 No.34
Drugs & Targets Oncomine Dx Target Test receives FDA approval as first NGS-based companion diagnostic for RET fusion + NSCLC September 11, 2020Vol.46 No.34
Drugs & Targets FDA issues alert about efficacy and potential safety concerns with atezolizumab in combination with paclitaxel for treatment of breast cancer September 11, 2020Vol.46 No.34
